Recent Updates
Recently added Catalysts
PPBT

Notice of 2018 Annual General Meeting

Key Takeaway: KITOV PHARMA LIMITED Notice of 2018 Annual General Meeting Notice is hereby given that the 2018 Annual General Meeting of Shareholders (the "Meeting" or the "Annual Meeting") of Kitov Pharma Limited ("Kitov" or the "Company") will be held at Kitov's executive offices at One

Full Press Release Details

KITOV PHARMA LIMITED
Notice of 2018 Annual General Meeting
Notice is hereby given
that the 2018 Annual General Meeting of Shareholders (the "Meeting" or the "Annual Meeting")
of Kitov Pharma Limited ("Kitov" or the "Company") will be held at Kitov's executive
offices at One Azrieli Center, Round Tower, 19th Floor, Tel Aviv, Israel on Wednesday, December 19, 2018, at 4:30 p.m.
local Israeli time, for the following purposes:
1. To review the Company's Financial Statements and Annual Report for the year ended December 31, 2017.
2. To review the compensation paid by the Company during 2017 to Somekh Chaikin, Certified Public Accountants (Israel), a member of KPMG International, the independent public accountants of the Company.
3. To approve an addition to the Company's amended and restated articles of association, with respect to establishing exclusive forums for certain litigation matters involving the Company.
4. To re-appoint each of Messrs. Isaac Israel and Simcha Rock, and Ms. Revital Stern-Raff to the Board of Directors, as members of the third class of directors, each to serve for a three-year term until the 2021 Annual General Meeting, and until their successors have been duly elected.
5. To approve an amendment to the terms of office and employment of Dr. John Paul Waymack, the Chairman of the Board of Directors and Chief Medical Officer of the Company.
6. To approve an amendment to the terms of office and employment of Mr. Isaac Israel a member of the Board of Directors and Chief Executive Officer of the Company.
7. To approve the terms of office and employment of Mr. Simcha Rock a member of the Board of Directors, with respect to his services as a consultant of the Company.
8. To approve a 1-for-20 reverse share split of the Company's ordinary shares, effective on the date to be announced by the Company, and to approve the applicable amendments to each of the Company's Memorandum of Association and Amended and Restated Articles of Association to reflect such reverse split.
9. To transact such other business as may properly come before the Meeting
of record at the close of business in New York on Wednesday, November 14, 2018 will be entitled to vote at the Annual Meeting.
Two shareholders who are present at the Annual Meeting, in person or by proxy or represented by their authorized persons, and who
hold in the aggregate twenty-five percent or more of the paid-up share capital of the Company, shall constitute a legal quorum.
Should no legal quorum be present one half hour after the scheduled time, the Meeting shall be adjourned to one week from
that day, at the same time and place.
the Israeli Companies Law 5759-1999 and Regulations enacted pursuant to such law, and as set forth in our Amended and Restated
Articles of Association, we are not required to physically deliver a notice of a shareholders meeting and a proxy statement. We
have prepared this Notice of Annual General Meeting of Shareholders, and will prepare the Proxy Statement, Voting Slip and Voting
Instruction Forms, (collectively, the "Proxy Materials") in accordance with applicable rules, regulations and
disclosure requirements in the State of Israel, as such are applicable to a Company whose securities are traded on both the Tel
Aviv Stock Exchange and the NASDAQ. Our Proxy Materials may not necessarily be mailed to beneficial shareholders in Israel, nor
to beneficial ADS holders in the United States.
The full set of Proxy
Materials are expected to be furnished to the Securities and Exchange Commission ("SEC") on Form 6-K on or before
November 14, 2018, and will be available to the public on the SEC's website at https://www.sec.gov. The Proxy Materials
will also be submitted to the Israeli Securities Authority and TASE, and available on the websites: www.magna.isa.gov.il
or www.maya.tase.co.il. This Notice of Annual General Meeting of Shareholders and the Proxy Materials will also be made
available on our corporate website at http://kitovpharma.investorroom.com/Shareholder-Meetings, as required under the
Companies Law and Regulations governing publication of this Notice of Annual General Meeting of Shareholders and distribution of
the Proxy Materials.
one or more shareholders holding 1% or more of the voting rights of the Company may request to include a proposal on the agenda
of a shareholders meeting (including proposing the nomination of a candidate to the Company's Board of Directors (the "Board
of Directors") for consideration by the Board of Directors) by submitting such proposal within seven days of publication
of the Company's notice with respect to its general meeting of shareholders (a "Meeting Agenda Addition").
Accordingly, any shareholder, or group of shareholders, holding 1% or more of the voting rights of the Company may request to include
a Meeting Agenda Addition proposal on the agenda of this Meeting by submitting such proposal in writing to the Company no
later than Friday, November 16, 2018, 4:00 p.m. Israel time, at the Company Offices, Attn: Avraham Ben-Tzvi, Adv. If a
Meeting Agenda Addition is to nominate a candidate for election to the Board of Directors, the proposing shareholder(s) must provide
(a) a declaration signed by the nominee and any other information required under the Companies Law, (b) all of the information
set forth under Regulation 26(a) of the Securities Regulations (Periodic and Immediate Reports), 5730-1970, (c) additional information
in respect of the nominee as would be required in response to the applicable disclosure requirements in Israel or abroad, including
those of Item 6A (directors and senior management), Item 6E (share ownership) and Item 7B (related party transactions) of Form
20-F of the SEC, to the extent applicable, (d) a representation made by the nominee of whether the nominee meets the objective
criteria for an independent director and/or statutory unaffiliated director of a company such as the Company under the Companies
Law and/or under any applicable law, regulation or stock exchange rules, in Israel or abroad, and if not, then an explanation of
why not, and (e) details of all relationships and understandings between the proposing shareholder(s) and the nominee.
shareholders wishing to express their position on an agenda item for this Meeting may do so by submitting a written Position Statement
("Position Statement") to the Company Offices, Attn: Avraham Ben-Tzvi, Adv. Any Position Statement received
will be furnished to the SEC on Form 6-K, and will be made available to the public on the SEC's website at http://www.sec.gov,
and in addition at http://www.magna.isa.gov.il or http://maya.tase.co.il. Position Statements should be submitted
to the Company no later than Sunday, December 9, 2018 at 4:00 p.m. Israel time. Any Position Statements so submitted
must comply with the requirements set forth under the Companies Law and any applicable regulations, including the Companies Regulations
(Voting in Writing and Position Statements), 5766-2005.
Beneficial ADS holders
in the United States should return their form of Voting Instruction Form for holders of the Company's ADSs by no later than
the date and time which will be set forth on such Voting Instruction Form. Proxies must be deposited at the Company Offices or
the place designated for the Meeting no later than 48 hours prior to the time scheduled for the Meeting. However, the Meeting chairman
is entitled to waive this requirement with respect to all participants at the Meeting, and to accept all the proxies at the commencement
of the Meeting, subject to the presentation of proof of share ownership.
All Voting Slips (together
with proofs of share ownership, and all documents required to be submitted therewith) must be delivered to the Company Offices
set forth above, such that the Voting Slip arrives no later 4 hours prior to the designated time of the Meeting, namely by no later
than on Wednesday, December 19, 2018, at 12:30 p.m. Israel Time. Voting via Electronic Voting Slips, which will be
delivered to the Company via the Electronic Voting System being operated pursuant to Section B of Chapter G'2 of the Securities
Law, 5728-1968, will be allowed until six (6) hours prior to the Meeting commencement, namely by no later than Wednesday,
December 19, 2018, 10:30 a.m. Israel Time.
By Order of the Board of Directors,
/s/ Avraham Ben-Tzvi
Avraham Ben-Tzvi, Adv.
On behalf of Kitov Pharma Ltd.
Last updated: Nov 9, 2018